ERG and neoplasm: We utilized the TIDE algorithm to predict the tumor immune response rate and found that cluster 2 had a significantly higher TIDE score than cluster 1 (p = 1.4 × 10−15), suggesting that patients in the ERG-low group might benefit more from immune checkpoint inhibitor therapy (ICBs) (Figure 6D).